Orient Pharma Co Ltd Company Profile
What is the competitive landscape for ORIENT PHARMA CO LTD
ORIENT PHARMA CO LTD has four approved drugs.
Summary for Orient Pharma Co Ltd
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Orient Pharma Co Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orient Pharma Co Ltd | PITAVASTATIN CALCIUM | pitavastatin calcium | TABLET;ORAL | 205932-003 | Feb 3, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Orient Pharma Co Ltd | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | CAPSULE;ORAL | 210729-001 | Apr 29, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Orient Pharma Co Ltd | GLYBURIDE | glyburide | TABLET;ORAL | 206483-001 | Feb 22, 2019 | AB1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Orient Pharma Co Ltd | CARISOPRODOL | carisoprodol | TABLET;ORAL | 205085-001 | Oct 28, 2014 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Orient Pharma Co Ltd | PITAVASTATIN CALCIUM | pitavastatin calcium | TABLET;ORAL | 205932-002 | Feb 3, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
